Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
Department
Adjust height of sidebar
KMap
Department
Pathology
15 active people
38 grants
Recent Grants
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
2023
·
$568.2K
colorectal cancer,
treatment,
clinical trial,
dkn-01,
chemotherapy
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers
2023
·
$509.8K
cancer,
chemotherapy,
clinical trial,
treatment,
combination therapy
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
2023
·
$494.2K
cancer,
immunotherapy,
clinical trials,
metastasis,
treatment comparison
Actuate 1801. Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3B) Inhibitor, as a Single Agent and Combined with Chemotherapy, in Patients with Refractory Hematologic Malignancies
2023
·
$432.5K
gsk-3b inhibitor,
hematologic malignancies,
chemotherapy
A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
2023
·
$253.9K
oncology,
clinical trial,
cancer treatment,
pharmacology,
molecular biology
University of Arizona Cancer Center - Cancer Center Support Grant
2022
·
$8.7M
cancer research,
medical oncology,
grants,
cancer treatment,
supportive care
Success, Health, Innovation, and Equity-Arizona Research Center (SHINE-ARC)
2022
·
$4.1M
health,
equity,
innovation,
research,
center
A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestional Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
2022
·
$497.7K
clinical trials,
oncology,
combination therapy,
mapk pathway mutations,
gastrointestinal malignancies
Quantitative MRI and Deep Learning Technologies for Classification of NAFLD
2022
·
$398.9K
quantitative mri,
deep learning,
nafld classification,
medical imaging,
machine learning
DNA methylation, Liquid Biopsy, and Pancreatic Cancer
2022
·
$391.1K
dna methylation,
liquid biopsy,
pancreatic cancer
Geographic and Environmental Health Equity in Kidney Precision Medicine
2022
·
$361.2K
geographic health,
environmental health,
kidney precision medicine,
health equity,
precision medicine
A Phase IIb Study of ALX148 in Combination With Anti-pd-1 and Cetuximab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
2022
·
$181.2K
immunotherapy,
colorectal cancer,
combination therapy,
metastatic cancer
A Randomized Phase II Study of Atezolizumab and A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC), HCRN GI19-405
2022
·
$112.9K
cancer,
immunotherapy,
clinical trial,
hepatocellular carcinoma,
treatment
AIDS and Cancer Specimen Resource (ACSR)- Impact of HIV-1 Infection on Epigenetic Regulations of Anti Tumor Immunity
2022
·
$56.3K
hiv-1 infection,
cancer specimen resource,
epigenetic regulations,
anti tumor immunity,
aids impact
TAF1, T-Type Channels, and X-linked Dystonia Parkinsonism
2022
·
$22.3K
channelopathies,
neurodegenerative disorders,
genetic disorders,
parkinsonism,
ion channels
Abdominal Adiposity in Early-Onset and Aggressive Clear Cell Renal Cell Carcinoma and Health Disparities
2021
·
$865.5K
cancer,
obesity,
health disparities,
renal cell carcinoma,
adiposity
Assessing Outcomes of Patients with Primary FSGS A Multicenter Real-World Observational Study
2021
·
$25.2K
kidney disease,
clinical outcomes,
multicenter,
fsgs
University of Arizona COVID-19 Serology Testing
2020
·
$3.5M
covid-19,
serology,
university,
testing,
arizona
ANCHOR- Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions (HSIL)
2020
·
$2.8M
anal cancer prevention,
hiv patients,
topical treatment,
ablative treatment,
high-grade squamous intraepithelial lesions
University of Arizona COVID-19 Serology Testing
2020
·
$1M
covid-19,
serology,
university,
testing,
arizona
People
Achyut Bhattacharyya
Department Head
Anil Rama Rao
Associate Professor
Alexis Elliott
Assistant Clinical Professor, Pathology - (Clinical Series Track)
Barun De
Professor
Belinda Sun
Associate Professor, Pathology - (Clinical Scholar Track)
Catherine Perry
Professor
Deborah Fuchs
Professor, Pathology - (Educator Scholar Track)
Erika Bracamonte
Professor
Hina Arif Tiwari
Professor
Mark Nelson
Professor
Maria Proytcheva
Professor, Pathology - (Clinical Scholar Track)
Demaretta Rush
Associate Professor, Pathology - (Clinical Scholar Track)
Monika Schmelz
Professor
David Nolte
Assistant Professor, Pathology - (Clinical Scholar Track)
Joel Addams
Assistant Professor, Pathology - (Clinical Scholar Track)
Research expenses history
Funding support
9 funding agencies since 2020